3/27/2013 8:37:58 AM
Patients in England and Wales with lung cancer should not have access to Pfizer's Xalkori through the NHS at the drug's current price, according to new draft guidance from cost-effectiveness body the National Institute for Health and Clinical Excellence (NICE). NICE said that despite being a clinically effective treatment, Xalkori (crizotinib) was not a cost-effective use of NHS resources for use in its approved indication of previously treated anaplastic-lymphoma-kinase-positive advanced non-small-cell lung cancer (NSCLC). According to NICE, a course of treatment with Xalkori would cost the NHS between £37,512 and £46,890 until disease progression, and a course after disease progression would be £51,579.
comments powered by